Wednesday, June 10, 2026
🇺🇸 FDA

Drug profile · INN

ophthalmic

ophthalmic is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 36
News articles 0
Drug details — ophthalmic
Class
—
Route
—
Patents
20
Programs
36
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

ophthalmic is an FDA-listed pharmaceutical active ingredient.

Key facts

INN ophthalmic

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. 0.05% Voclosporin Ophthalmic Solution (VOS) Phase 3 · Aurinia Pharmaceuticals · Dry Eye Syndrome
  2. ADX-102 Ophthalmic Solution (0.5%) Phase 3 · Aldeyra Therapeutics · Non-infectious Anterior Uveitis
  3. Aceclidine+Brimonidine combination ophthalmic solution Phase 3 · LENZ Therapeutics · Presbyopia
  4. CLOBOF3-17IA03 Phase 3 · Tillomed Laboratories · Inflammation and pain associated with ocular surgery
  5. K-321-301 Phase 3 · George Institute for · Fuchs Endothelial Corneal Dystrophy
  6. NN9535-4352 Phase 3 · NovoThirteen · While it is well-established that long-term good glycaemic c
  7. Reproxalap Ophthalmic Solution (0.25%) Phase 3 · Aldeyra Therapeutics · Dry Eye
  8. Reproxalap Ophthalmic Solution (0.25%) Phase 3 · Aldeyra Therapeutics · Allergic Conjunctivitis

Related patents

Browse patents

  1. US 12364680

    Compounds for treating ophthalmic diseases and disorders

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11925686

    Materials for phototherapies of ophthalmic diseases

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11845989

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11820982

    Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11786518

    Ophthalmic formulations and uses thereof

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11767526

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11730716

    Compounds for treating ophthalmic diseases and disorders

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11684570

    Pharmaceutical ophthalmic compositions

    Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11512309

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. CN 115348859

    Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11439590

    Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11285163

    Ophthalmic solution

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11278493

    Ophthalmic formulations providing durable ocular lubrication

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10973871

    Ophthalmic compositions

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 2019151500

    OPHTHALMIC VISCOELASTIC COMPOSITIONS

    Expires Wed May 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10265375

    Ophthalmic compositions

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10016388

    Ophthalmic lens, intraocular lens, and ophthalmic lens package having ophthalmic lens

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9844530

    Ophthalmic solutions for glaucoma and conjunctivitis treatment

    Expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9814695

    Ophthalmic solutions for glaucoma and conjunctivitis treatment

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9804298

    Ophthalmic lens material

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ophthalmic?

ophthalmic is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.